Six-month Follow-up of Hepatitis A Antibodies in Newborn Infants in Diyarbakir Province and Its Region

Abstract

Objective: In this study, we aimed to determine the frequency and persistence of maternally transmitted anti-HAV antibodies in healthy newborn infants of people living in Diyarbakır province, which is located in a high HAV endemicity area, and its neighbourhood. Material and Method: In our study, infants born between October 1999 and January 2000 in the Gynaecology and Obstetrics Clinic of Diyarbakır Dicle University and registered in the Department of Paediatrics were followed up for 12 months. Blood samples were collected from all babies at birth, third and sixth months. Results: A total of 112 healthy newborns were included in the study. Of the infants, 62 (55.3%) were boys and 50 (44.7%) were girls. Demographic and medical information was obtained from the parents. Seropositivity was 90.2% at birth, 87.5% at 1 month, 39.3% at 6 months and 28.6% at one year. Conclusion: It was emphasised that our region has a high endemicity for HAV and in order to reduce HAV infection, socioeconomic level should be increased, hygiene should be given importance and immunisation with vaccine should be performed when appropriate conditions are met.

Keywords

• Hepatitis A
• Newborn
• Hepatitis A vaccine

References

1. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis A and E: Update on prevention and epidemiology. Vaccine. 2010 Jan;28(3):583–8.
2. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004 Dec 16;132(6):1005–22.
3. Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat. 2008 Oct 27;15(s2):69–72.
4. Gans HA, Maldonado YA. Loss of Passively Acquired Maternal Antibodies in Highly Vaccinated Populations: An Emerging Need to Define the Ontogeny of Infant Immune Responses. J Infect Dis. 2013 Jul 1;208(1):1–3.
5. Palfi M, Selbing A. Placental Transport of Maternal Immunoglobulin G. Am J Reprod Immunol. 1998 Jan;39(1):24–6.
6. Saji F. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999 May 1;4(2):81–9.
7. Siegrist CA. The Challenges of Vaccine Responses in Early Life: Selected Examples. J Comp Pathol. 2007 Jul;137:S4–9. Derya A, Necmi A, Emre A, Akgün Y. Decline of maternal hepatitis a antibodies during the first 2 years of life in infants born in Turkey. Am J Trop Med Hyg. 2005 Aug;73(2):457–9.
8. Kanra G, Tezcan S, Badur S, Turkish National Study Team. Hepatitis A seroprevalence in a random sample of the Turkish population by simultaneous EPI cluster and comparison with surveys in Turkey. Turk J Pediatr. 2002;44(3):204–10.

9. Vidor E. Vaccination of Newborns against Hepatitis A in the Presence of Maternally Derived Antibodies. J Comp Pathol. 2007 Jul;137:S42–5.
10. Lieberman JM, Chang S ju, Partridge S, Hollister JC, Kaplan KM, Jensen EH, et al. Kinetics of maternal hepatitis and antibody decay in infants: implications for vaccine use. Pediatr Infect Dis J. 2002 Apr;21(4):347–8.
11. De Silvestri A, Avanzini MA, Terulla V, Zucca S, Polatti F, Belloni C. Decline of maternal hepatitis A virus antibody levels in infants. Acta Paediatr. 2002;91(8):882–4.
12. Wasley A. Hepatitis A in the Era of Vaccination. Epidemiol Rev. 2006 Jun 1;28(1):101–11.
13. Glezen W. Effect of maternal antibodies on the infant immune response. Vaccine. 2003 Jul 28;21(24):3389–92.
14. Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J, et al. Immunogenicity of an Inactivated Hepatitis A Vaccine in Infants and Young Children. Pediatr Infect Dis J. 2007 Feb;26(2):116–22.
15. Cortes-Martins H, Matos R, Moura S, Almeida L, Ferreira S, Manita C, et al. Anti-HAV IgG seroprevalence in Lisbon region residents: Preliminary results from the National Serological Survey 2015–2016. J Clin Virol. 2016 Sep;82:S79–80.
16. Arvas G, Kaya B, Berktaş M. The Seroprevalance of Acute Hepatitis A in 0-18 Age Group Children who Applied to Igdır State Hospital. J Pediatr Infect. 2011 Dec 15;5(4):129–31.
17. Yilmaz A. Hepatitis A seroprevalence in Erzurum, Turkey. Ann Agric Environ Med. 2020 Sep 11;27(3):481–4.
18. Alhan E, Kozanoglu B, Tumgor G, Celik U, Yaman A, Bozdemir N. Epidemiological shift of hepatitis A in central Adana, Turkey. Turkish J Gastroenterol. 2015 Apr 22;25(1):6–8.
19. Kovarik J, Siegrist C. Optimization of vaccine responses in early life: The role of delivery systems and immunomodulators. Immunol Cell Biol. 1998 May;76(3):222–36.
20. Brinkhof MWG, Mayorga O, Bock J, Heininger U, Herzog C. Kinetics of maternally acquired anti-hepatitis A antibodies: Prediction of waning based on maternal or cord blood antibody levels. Vaccine. 2013 Mar;31(11):1490–5.
21. Kalyoncu D, Urganci N. Response to hepatitis A and B vaccination in patients with chronic hepatitis C: 8-year follow-up. Paediatr Int Child Health. 2012 Aug 12;32(3):136–9.